You are here: Industry Insights > InnoCare

News List

InnoCare Announces Approval of HIBRUKA (Orelabrutinib) for the Treatment of Mantle Cell Lymphoma in Singapore PharmaSources.com
November 22, 2022
InnoCare Pharma that HIBRUKA (orelabrutinib) has been approved by the Health Sciences Authority (HSA) of Singapore for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (R/R MCL).
InnoCare Releases 2022 Third Quarter Results: Star Board Listing for Long-term Growth and Rapid Increase of Orelabrutinib Sales PharmaSources.com
November 16, 2022
InnoCare Pharma announced 2022 third quarter results and latest corporate development.
InnoCare Announces Priority Review of Orelabrutinib for the Treatment of R/R MZL by NMPA PharmaSources.com
September 06, 2022
So far, no BTK inhibitor has ever been approved for treating patients with R/R MZL in China, and hope that orelabrutinib can fill the gap in this therapeutic area.
Latest Data of InnoCare’s Robust Oncology Pipelines Presented at the 2022 ASCO Annual Meeting PharmaSources.com
June 07, 2022
Latest data of InnoCare’s robust oncology pipeline were presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
InnoCare Announces Dosing of First Patient in Clinical Trial of RTK Inhibitor ICP-033 in China PharmaSources.com
March 30, 2022
InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases...
InnoCare Announces Approval of Clinical Trial of TYK2 JH2 Allosteric Inhibitor ICP-488 in China PharmaSources.com
March 28, 2022
InnoCare Pharmaannounced today that the company has received Investigational New Drug (IND) approval of clinical trial from the NMPA...
InnoCare Releases 2021 Annual Results and Business Highlights InnoCare
March 23, 2022
InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing...
InnoCare Announces Acceptance of Supplemental New Drug Application for Orelabrutinib in Relapsed or Refractory Waldenstr?m’s Macroglobulinemia in China March 14, 2022
InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company, announced recently...
InnoCare to Host 2021 Full Year Earnings Call on March 23, 2022 InnoCare Pharma
March 11, 2022
InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on cancer and autoimmune diseases...
InnoCare to Attend Upcoming Investor Conferences to Share Latest Company Development PharmaSources.com
January 07, 2022
InnoCare Pharma (HKEX: 09969), a leading biotech company, announced today that the company executives will attend the upcoming investor conferences organized by Morgan Stanley and UBS to share company’s latest development.